Go Pro
→ How Long Does $2.5M Last in Retirement? (From SmartAsset) (Ad)tc pixel Free MBAI Stock Alerts

Check-Cap (MBAI) Competitors

Check-Cap logo
$6.50 +0.02 (+0.31%)
As of 09/3/2026 04:00 PM Eastern
Compare

MBAI vs. TELA, ARAY, QTEX, IINN, and MODD

Should you buy Check-Cap stock or one of its competitors? Check-Cap's main competitors and comparable companies include TELA Bio (TELA), Accuray (ARAY), Inspira Technologies OXY B.H.N. (QTEX), Inspira Technologies OXY B.H.N. (IINN), and Modular Medical (MODD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Check-Cap compare to TELA Bio?

Check-Cap (NASDAQ:MBAI) and TELA Bio (NASDAQ:TELA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 94.4% of TELA Bio shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by company insiders. Comparatively, 5.1% of TELA Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

TELA Bio has a consensus target price of $2.20, suggesting a potential upside of 181.69%. Given TELA Bio's stronger consensus rating and higher probable upside, analysts plainly believe TELA Bio is more favorable than Check-Cap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TELA Bio
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, TELA Bio had 1 more articles in the media than Check-Cap. MarketBeat recorded 4 mentions for TELA Bio and 3 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.00 beat TELA Bio's score of -0.28 indicating that Check-Cap is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TELA Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Check-Cap has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, TELA Bio has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Check-Cap has a net margin of 0.00% compared to TELA Bio's net margin of -51.53%. Check-Cap's return on equity of 0.00% beat TELA Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
TELA Bio -51.53%-1,320.81%-59.39%

Check-Cap has higher earnings, but lower revenue than TELA Bio. TELA Bio is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$14.07N/A
TELA Bio$80.28M0.44-$38.83M-$0.77N/A

Summary

TELA Bio beats Check-Cap on 9 of the 15 factors compared between the two stocks.

How does Check-Cap compare to Accuray?

Check-Cap (NASDAQ:MBAI) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.

Check-Cap has a net margin of 0.00% compared to Accuray's net margin of -12.24%. Check-Cap's return on equity of 0.00% beat Accuray's return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Accuray -12.24%-97.85%-10.82%

Accuray has a consensus price target of $2.00, suggesting a potential upside of 651.88%. Given Accuray's stronger consensus rating and higher probable upside, analysts plainly believe Accuray is more favorable than Check-Cap.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Accuray
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

In the previous week, Check-Cap had 2 more articles in the media than Accuray. MarketBeat recorded 3 mentions for Check-Cap and 1 mentions for Accuray. Accuray's average media sentiment score of 0.68 beat Check-Cap's score of 0.00 indicating that Accuray is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Accuray
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 64.1% of Accuray shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 2.4% of Accuray shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Check-Cap has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market. Comparatively, Accuray has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Check-Cap has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$14.07N/A
Accuray$401.95M0.08-$49.19M-$0.40N/A

Summary

Accuray beats Check-Cap on 8 of the 14 factors compared between the two stocks.

How does Check-Cap compare to Inspira Technologies OXY B.H.N.?

Check-Cap (NASDAQ:MBAI) and Inspira Technologies OXY B.H.N. (NASDAQ:QTEX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Inspira Technologies OXY B.H.N.
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Inspira Technologies OXY B.H.N. had 1 more articles in the media than Check-Cap. MarketBeat recorded 4 mentions for Inspira Technologies OXY B.H.N. and 3 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.00 equaled Inspira Technologies OXY B.H.N.'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inspira Technologies OXY B.H.N.
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 0.5% of Check-Cap shares are held by insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Check-Cap has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 4.24, meaning that its stock price is 324% more volatile than the broader market.

Check-Cap has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$14.07N/A
Inspira Technologies OXY B.H.N.$290K101.45-$13.22MN/AN/A

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Inspira Technologies OXY B.H.N. N/A N/A N/A

Summary

Inspira Technologies OXY B.H.N. beats Check-Cap on 5 of the 6 factors compared between the two stocks.

How does Check-Cap compare to Inspira Technologies OXY B.H.N.?

Check-Cap (NASDAQ:MBAI) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

1.1% of Check-Cap shares are held by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are held by institutional investors. 0.5% of Check-Cap shares are held by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Inspira Technologies OXY B.H.N.
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Check-Cap has higher earnings, but lower revenue than Inspira Technologies OXY B.H.N..

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$14.07N/A
Inspira Technologies OXY B.H.N.$289K101.55-$13.22MN/AN/A

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Inspira Technologies OXY B.H.N. N/A N/A N/A

Check-Cap has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.16, meaning that its share price is 116% more volatile than the broader market.

In the previous week, Check-Cap had 1 more articles in the media than Inspira Technologies OXY B.H.N.. MarketBeat recorded 3 mentions for Check-Cap and 2 mentions for Inspira Technologies OXY B.H.N.. Check-Cap's average media sentiment score of 0.00 equaled Inspira Technologies OXY B.H.N.'saverage media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inspira Technologies OXY B.H.N.
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Inspira Technologies OXY B.H.N. beats Check-Cap on 4 of the 6 factors compared between the two stocks.

How does Check-Cap compare to Modular Medical?

Modular Medical (NASDAQ:MODD) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Modular Medical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Modular Medical had 1 more articles in the media than Check-Cap. MarketBeat recorded 4 mentions for Modular Medical and 3 mentions for Check-Cap. Modular Medical's average media sentiment score of 0.20 beat Check-Cap's score of 0.00 indicating that Modular Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Modular Medical
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Check-Cap
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Modular Medical has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

27.5% of Modular Medical shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 7.1% of Modular Medical shares are held by company insiders. Comparatively, 0.5% of Check-Cap shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Check-Cap is trading at a lower price-to-earnings ratio than Modular Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Modular MedicalN/AN/A-$28.24M-$8.69N/A
Check-CapN/AN/A$4.14M-$14.07N/A

Check-Cap's return on equity of 0.00% beat Modular Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Modular MedicalN/A -292.14% -222.79%
Check-Cap N/A N/A N/A

Summary

Modular Medical beats Check-Cap on 6 of the 10 factors compared between the two stocks.

Get Check-Cap News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBAI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBAI vs. The Competition

Export
MetricCheck-CapHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.91M$5.81B$7.26B$12.73B
Dividend YieldN/A1.76%2.53%8.86%
P/E Ratio-0.4625.92273.2925.38
Price / SalesN/A73.28613.4592.55
Price / Cash1.6333.1477.8252.26
Price / Book1.976.0412.896.14
Net Income$4.14M$150.03M$3.47B$349.01M
7 Day Performance-1.22%-1.32%0.60%-0.27%
1 Month Performance-19.25%1.27%5.73%0.68%
1 Year PerformanceN/A9.88%25.35%14.84%

Check-Cap Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBAI
Check-Cap
0.4986 of 5 stars		$6.50
+0.3%		N/AN/A$8.91MN/AN/A80
TELA
TELA Bio
3.1574 of 5 stars		$0.75
-4.9%		$2.20
+192.4%		-52.7%$33.78M$79.91MN/A120
ARAY
Accuray
2.6947 of 5 stars		$0.26
+2.1%		$2.00
+669.2%		-81.8%$31.05M$401.95MN/A1,040
QTEX
Inspira Technologies OXY B.H.N.
0.1884 of 5 stars		$0.82
+2.2%		N/AN/A$29.35M$290KN/A20
IINN
Inspira Technologies OXY B.H.N.
0.0102 of 5 stars		$0.80
-3.5%		N/A-30.2%$28.71M$289KN/A20

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MBAI) was last updated on 9/4/2026 by MarketBeat.com Staff.
From Our Partners
A Simple Guide to Options Trading While It's Still Free
A free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...
True Market Insiders | Sponsoredtc pixel
Before Anthropic becomes impossible to ignore...
Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...
The Oxford Club | Sponsoredtc pixel
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Major Buy Alert Issued for September 30th
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...
Investors Alley | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1984, a 10000 dollar stake in Apple could have grown to 25 million dollars for early investors who simply g...
Eagle Publishing | Sponsoredtc pixel